SCHEMBL5154528

SCHEMBL5154528

O=C(O)C1CCCN2C(=O)CCC(N3C(=O)c4ccccc4C3=O)C(=O)N12

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACE P12821 7/20 0.51
MME P08473 3/20 0.51
ALDH1A1 P00352 2/20 0.41
CHRM2 P08172 1/20 0.41
OPRM1 P35372 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
IKZF3 Q9UKT9 1/20 0.41
CYP1A2 P05177 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CASP1 P29466 5/20 0.40
IL1B P01584 1/20 0.38
HSD17B10 Q99714 1/20 0.37
MAP1LC3B Q9GZQ8 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5154520 1.00 ACE (0.51) ACEMMEALDH1A1CHRM2OPRM1
SCHEMBL5154165 1.00 ACE (0.51) ACEMMEALDH1A1CHRM2OPRM1
SCHEMBL5158143 1.00 ACE (0.51) ACEMMEALDH1A1CHRM2OPRM1
SCHEMBL5154587 1.00 ACE (0.51) ACEMMEALDH1A1CHRM2OPRM1
SCHEMBL10565078 0.93 ACE (0.49) ACEMMEALDH1A1CHRM2OPRM1
SCHEMBL11205197 0.93 ACE (0.49) ACEMMEALDH1A1CHRM2OPRM1
SCHEMBL7344268 0.93 ACE (0.49) ACEMMEALDH1A1CHRM2OPRM1
SCHEMBL7344257 0.93 ACE (0.49) ACEMMEALDH1A1CHRM2OPRM1
SCHEMBL10567702 0.89 ACE (0.53) ACEMMEALDH1A1CHRM2OPRM1
SCHEMBL7034916 0.87 MME (0.41) ACEMMEALDH1A1CHRM2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6433164-B1 None US disclosed
EP-1073673-B1 OCTAHYDRO-6,10-DIOXO-6H-PYRIDAZINO/1,2-a/ /1,2/DIAZEPIN-1-CARBOXYLIC ACID DERIVATIVES, PREPARATION METHOD AND USE FOR PREPARING THERAPEUTICALLY ACTIVE COMPOUNDS AVENTIS PHARMA SA (FR) 2007-01-10 EP disclosed
EP-0955310-B1 New derivatives of (3,4,7,8,9,10)-hexahydro-6,10-dioxo-6H-pyridazino /1,2-a/ /1,2/ diazepine-1-carboxylic acid, process for their preparation and use for preparation of pharmaceutical agents AVENTIS PHARMA SA (FR) 2004-10-13 EP disclosed
US-6433164-B2 SUBSTITUTED ON RING CARBON #9 BY A PRIMARY AMINE WHICH MAY OR MAY NOT BE PROTECTED; DEHYDROGENATION OF THE OCTOHYDRO DERIVATIVE; DRUGS AVENTIS PHARMA S.A. (FR) 2002-08-13 US disclosed
US-20010002422-A1 (3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2,] diazepine-1-carboxylic-acid derivatives HOECHST MARION ROUSSEL 2001-05-31 US disclosed
EP-0955310-A1 New derivatives of (3,4,7,8,9,10)-hexahydro-6,10-dioxo-6H-pyridazino /1,2-a/ /1,2/ diazepine-1-carboxylic acid, process for their preparation and use for preparation of pharmaceutical agents HOECHST MARION ROUSSEL (FR) 1999-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010002422-A1 (3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2,] diazepine-1-carboxylic-acid derivatives GRIK1, GRIK2, ATXN2L ACE 1357/4885MME 4589/4885ALDH1A1 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.